Sound waves and antineoplastic drugs: The possibility of an enhanced combined anticancer therapy

Journal of Medical Ultrasonics

Volumn 29, Issue WINTER, 2002, Pages 173-187

  Feril Jr , Loreto B ^a   Kondo, Takashi ^a   Umemura, Shin ichiro ^b   Tachibana, Katsuro ^c   Manalo, Angelo H ^d   Riesz, Peter ^e  

^a UNIVERSITY OF TOYAMA   (Japan)

^b HITACHI LTD   (Japan)

^c FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d MINDANAO STATE UNIVERSITY ILIGAN INSTITUTE OF TECHNOLOGY   (Philippines)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti cancer agent; Combined anticancer therapy; Shock wave; Ultrasound

Indexed keywords

3' DEAMINO 2' FLUORO 3' HYDROXYDOXORUBICIN 14 PIMELATE; ALBUNEX; AMPHOTERICIN B; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACTINOMYCIN; DAUNORUBICIN; DIAZIQUONE; DIMETHYL SULFOXIDE; DOXORUBICIN; ETOPOSIDE; FS 069; MELPHALAN; METHOTREXATE; MITOMYCIN C; N,N DIMETHYLFORMAMIDE; NISOLDIPINE; PHEOPHORBIDE; PIRARUBICIN; PROCARBAZINE; ROSE BENGAL; SEMUSTINE; THIOTEPA; UNINDEXED DRUG; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; CELL PERMEABILIZATION; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; EXTRACORPOREAL LITHOTRIPSY; HUMAN; MULTIMODALITY CANCER THERAPY; NONHUMAN; RADIATION RESPONSE; REVIEW; TEMPERATURE; THERMOREGULATION; TREATMENT INDICATION; TREATMENT OUTCOME; ULTRASOUND THERAPY;

EID: 0036964879     PISSN: 13441388     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf02480848     Document Type: Review

References (117)

1. Kremkau FW: Cancer therapy with ultrasound: a historical review. J Clin Ultrasound 1979; 7: 287-300.
2. Kondo T, Kano E: The possibility of ultrasonic cancer therapy and some of the difficulties: implications of the thermal and nonthermal effects. Jpn J Hyperthermic Oncol 1990; 6: 1-18.
3. Kondo T, Umemura S, Tanabe K, et al: Novel therapeutic application of ultrasound: utilization of thermal and cavitational effects. Jpn J Hyperthermic Oncol 2000; 16: 203-216.
4. National Council on Radiation and Measurements: Historical Perspectives. In: Biological Effects of Ultrasound: Mechanisms and Clinical Implications. Report No. 74. Bethesda, Md: NCRP 1983; pp. 5-6.
5. Hill CR: Cited by: Kremkau FW. Cancer therapy with ultrasound: a historical review. J Clin Ultrasound 1979; 7: 287-300.
6. Chen L, Rivens I, ter Haar G, et al: Histological changes in rat liver tumors treated with high-intensity focused ultrasound. Ultrasound Med Biol 1990; 19: 67-74.
7. Suslick KS: Sonochemistry: Science 1990; 247: 1439-1445.
8. Riesz P, Kondo T: Free radical formation induced by ultrasound and its biological implications. Free Radic Biol Med 1992; 13: 247-270.
9. Nyborg WL: Mechanisms. In: Nyborg, WL and Ziskin, MC, eds. Biological Effects of Ultrasound. New York, Churchil Livingstone, 1985; pp. 23-33.
10. Saad A, Hahn G: Ultrasound enhanced drug toxicity on Chinese hamster ovary cells in vitro. Cancer Res 1989; 49: 5931-5934.
11. Loverock P, ter Haar G, Ormerod M, et al: The effect of ultrasound on the cytotoxicity of adriamycin. Br J Radiol 1990; 63: 542-546.
12. Harrison G, Balcer-Kubiczek E, Gutierrez P: In vitro action of continuous-wave ultrasound combined with adriamycin, x-rays or hyperthermia. Radiat Res 1996; 145: 98-101.
13. Umemura S, Yumita N, Okano Y, et al: Sonodynamically-induced in vitro cell damage enhanced by adriamycin. Cancer Lett 1997; 121: 195-201.
14. Yumita N, Kaneuchi M, Okano Y, et al: Sonodynamically induced cell damage with 4'-Otetrahydropyranyladriamycin, THP. Anticancer Res 1999; 19: 281-284.
15. Tachibana K, Uchida T, Tamura K, et al: Enhanced cytotoxic effect of Ara-C by low intensity ultrasound to HL-60 cells. Cancer Lett 2000; 147: 189-194.
16. Hering ER, Shepstone BJ: Observations on the combined effect of ultrasound and certain cytoxics on the growth of the roots of Zea mays. Br J Radiol 1977; 50: 32-37.
17. Umemura S, Yumita N, Nishigaki R: Enhancement of ultrasonically induced cell damage by a galliumporphyrin complex, ATX-70. Jpn J Cancer Res 1993; 84: 582-588.
18. Umemura S, Yumita N, Nishigaki R, et al: Mechanism of cell damage by ultrasound in combination with hematoporphyrin. Jpn J Cancer Res 1990; 81: 962-966.
19. Yumita N, Nishigaki R, Umemura K, et al: Hematoporphyrin as a sensitizer of cell-damaging effect of ultrasound. Jpn J Cancer Res 1989; 80: 219-222.
20. Miyoshi N, Misik V, Riesz P: Sonodynamic toxicity of gallium-porphyrin analogue ATX-70 in human leukemia cells. Radiat Res 1997; 148: 43-47.
21. Uchida T, Tachibana K, Hisano S, et al: Elimination of adult T cell leukemia cells by ultrasound in the presence of porfimer sodium. Anticancer Drugs 1997; 8: 329-335.
22. Tachibana K, Uchida T, Hisano S, et al: Eliminating adult T-cell Leukaemia cells by ultrasound. Lancet 1997; 349: 325.
23. Yumita N, Umemura S, Nishigaki R: Ultrasonically induced cell damage enhanced by photofrin II: mechanism of sonodynamic activation. In Vivo 2000; 14: 425-430.
24. Umemura S, Yumita N, Umemura K, et al: Sonodynamically induced effect of rose Bengal on isolated sarcoma 180 cells. Cancer Chemother Pharmacol 1999; 43: 389-393.
25. Yumita N, Umemura S, Kaneuchi M, et al: Sonodynamically-induced cell damage with fluorinated anthracycline derivative, FAD 104. Cancer Lett 1998; 125: 209-214.
26. Sakusabi N, Okada K, Sato K, et al: Enhanced sonodynamic antitumor effect of ultrasound in the presence of nonsteroidal anti-inflammatory drugs. Jpn J Cancer Res 1999; 90: 1146-1151.
27. Ward M, Wu J, Chiu JF: Ultrasound-induced cell lysis and sonoporation enhanced by contrast agents. JAcoust Soc Am 1999; 105: 2951-2957.
28. Yumita N, Okumura A, Nishigaki R, et al: The combination treatment of ultrasound and antitumor drugs on Yoshida sarcoma. Jpn J Hyperthermic Oncol 1987; 3: 175-182.
29. Saad A, Hahn G: Ultrasound-enhanced effects of adriamycin against murine tumors. Ultrasound Med Biol 1992; 18: 715-723.
30. Yang R, Reilly CR, Rescorla FJ, et al: Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg 1992; 27: 246-150.
31. Yang R, Reilly CR, Rescorla FJ, et al: High-intensity focused ultrasound in the treatment of experimental liver cancer. Arch Surg 1991; 126: 1009-1010.
32. More W, Lopez RM, Matthews DE, et al: Evaluation of high-intensity therapeutic ultrasound irradiation in the treatment of experimental hepatoma. J Pediatr Surg 1989; 24: 30-33.
33. Longo F, Tomashefsky P, Rivin B, et al: Interaction of ultrasonic hyperthermia with two alkylating agents in a murine bladder tumor. Cancer Res 1983; 43: 3231-3235.
34. Senapati N, Houchens D, Ovejera A, et al: Ultrasonic hyperthermia and drugs as therapy for human tumor xenografts. Cancer Treat Rep 1982; 66: 1635-1639.
35. Tacker J, Anderson R: Delivery of antitumor drug to bladder cancer by use of phase transition liposomes and hyperthermia. J Urol 1982; 127: 1211-1214.
36. Elkon D, Lacher DA, Rinehart L, et al: Effect of ultrasound-induced hyperthermia and cisdiamminedichloride platinum II on murine renal function. Cancer 1982; 49: 25-29.
37. Yumita N, Sasaki K, Umemura S, et al: Sonodynamically induced antitumor effect of galliumporphyrin complex by focused ultrasound on experimental kidney tumor. Cancer Lett 1996; 112: 79-86.
38. Jin Z, Miyoshi N, Ishiguro K, et al: Combination effect of photodynamic and sonodynamic therapy on experimental skin squamous cell carcinoma in C3H/HeN mice. J Dermatol 2000; 27: 294-306.
39. Yumita N, Sasaki K, Umemura S, et al: Sonodynamically induced antitumor effect of galliumporphyrin complex by focused ultrasound on experimental kidney tumor. Cancer Lett 1997; 112: 79-86.
40. Sasaki K, Yumita N, Nishigaki R, et al: Antitumor effect sonodynamically induced by focused ultrasound in combination with Ga-porphyrin complex. Jpn J Cancer Res 1998; 89: 452-456.
41. Yumita N, Nishigaki R, Umemura S: Sonodynamically induced antitumor effect of Photofrin II on colon 26 carcinoma. J Cancer Res Clin Oncol 2000; 126: 601 -606.
42. Sur P, Ghosh P, Bag SP, et al: On the inhibitory activities of a new boron compound and ultrasound against the mouse ascites tumour. Chemotherapy 1999; 45: 360-369.
43. Kremkau FW, Kaufmann JS, Walker MM, et al: Ultrasonic enhancement of nitrogen mustard cytotoxicity in mouse leukemia. Cancer 1976; 37: 1643-1647.
44. Harrison G, Balcer-Kubiczek EK, Eddy HA: Potentiation of chemotherapy by low-level ultrasound. Int J Radiat Biol 1991; 59: 1453-1466.
45. Yumita N, Nishigaki R, Sakata I, et al: Sonodynamically induced antitumor effect of 4-formyloximethylidene-3-hydroxy-2-vinyl-deuterioporphynyl (IX)- 6,7-diaspartic acid (ATX-S10). Jpn J Cancer Res 2000; 91: 255-260.
46. Umemura K, Yumita N, Nishigaki R, et al: Sonodynamically induced antitumor effect of pheophorbide a. Cancer Lett 1996; 102: 151-157.
47. Brayman AA, Coppage ML, Vaidya S, Miller MW: Transient poration and cell surface receptor removal from human lymphocytes in vitro by 1 MHz ultrasound. Ultrasound Med Biol 1999; 25: 999-1008.
48. Tachibana K, Uchida T, Ogawa K, et al: Induction of cell membrane porosity by ultrasound. Lancet 1999; 353: 1409.
49. Hahn GM, Braun J, Har-Kedar I: Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (or bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci USA 1975; 72: 937-940.
50. Kondo T, Kano E: Enhancement of hyperthermic cell killing by non-thermal effect of ultrasound. Int J Radiat Biol 1987; 51: 157-166.
51. Longo FW, Longo WE, Tomashefsky P, et al: Interaction of ultrasound with neoplastic tissue. Local effect on subcutaneously implanted Furth-Columbia rat Wilm's tumor. Urology 1975; 6: 631-634.
52. Yumita N, Umemura S, Magario N, et al: Membrane lipid peroxidation as a mechanism of sonodynamically induced erythrocyte lysis. Int J Radiat Biol 1996; 69: 397-404.
53. Kondo T, Kano E: Effect of free radicals induced by ultrasonic cavitation on cell killing. Int J Radiat Biol 1988; 54: 437-486.
54. Hristov PK, Petrov LA, Russanov EM: Lipid peroxidation induced by ultrasound in Ehrlich ascitis tumor cells. Cancer Lett 1997; 121: 7 -10.
55. Kessel D, Jeffers R, Fowlkes JB, et al: Effects of sonodynamic and photodynamic treatment on cellular thiol levels. J Photochem Photobiol B: Biol 1996; 32: 103-106.
56. Russo A, Mitchell JB: Potentiation and protection of doxorubicin cytotoxicity by cellular glutathione modulation. Cancer Treat Rep 1985; 69: 1293-1296.
57. Tata D, Hahn G, Dunn F: Ultrasonic absorption frequency dependence of two widely used anti-cancer drugs: doxorubicin and daunorubicin. Ultrasonics 1993; 31: 447-450.
58. Misik V, Riesz P: Free radical intermediates in sonodynamic therapy. Ann N Y Acad Sci 2000; 899: 335-348.
59. Misik V, Riesz P: Peroxyl radical formation in aqueous solutions of N,N-dimethylformamide, N-methylformamide, and dimethylsulfoxide by ultrasound: implications for sonosensitized cell killing. Free Radic Biol Med 1996; 20: 129-138.
60. Riesz P, Kondo T, Krishna MC: Free radical formation by ultrasound in aqueous solutions: a spin trapping study. Free Radic Res Comms 1990; 10: 27-35.
61. Sinha BK, Mimnaugh EG: Free radical and anticancer drug resistance: oxygen free radicals in the mechanisms of drug cytotoxicity and resistance by certain tumors. Free Radic Biol Med 1990; 8: 567-581.
62. Naffrechoux E, Chanoux S, Petrier C, et al: Sonochemical and photochemical oxidation of organic matter. Ultrason Sonochem 2000; 7: 255-259.
63. Worthington AE, Thompson J, Rauth AM, Hunt JW: Mechanism of ultrasound enhanced porphyrin cytotoxicity. Part I: A search for free radical effects. Ultrasound Med Biol 1997; 23: 1095-1105.
64. Simon R, Ho SY, Lange S, et al: Applications of lipidcoated microbubble ultrasonic contrast to tumor therapy. Ultrasound Med Biol 1993; 19: 123 -125.
65. Tata D, Biglow J, Wu J, et al: Ultrasound-enhanced hydroxyl radical production from two clinically employed anticancer drugs, adriamycin and mitomycin C. Ultrason Sonochem 1996; 3: 39-45.
66. Lusthof KJ, de Mol NJ, Richter W, et al: Redox cycling of potential antitumor aziridinyl quinones. Free Radic Biol Med 1992; 13: 599-608.
67. Misik V, Miyoshi N, Riesz P: EPR spin trapping study of the decomposition of azo compounds in aqueous solutions by ultrasound: potential for use as sonodynamic sensitizers for cell killing. Free Radic Res 1996; 25: 13-22.
68. Kapp DS, Hahn GM: Thermosensitization by sulfhydryl compounds of exponential growing Chinese hamster cells. Cancer Res 1979; 39: 4630-4635.
69. Marmor JB, Kozak D, Hahn GM: Effects of systemically administered bleomycin or adriamycin with local hyperthermia on primary tumor and lung metastases. Cancer Treat Rep 1979; 63: 1279-1290.
70. Hahn GM: Potential for therapy of drugs and hyperthermia. Cancer Res 1979; 39: 2264-2268.
71. Barlogie B, Corry PM, Drewinko B: In vitro thermochemotherapy of human colon cancer cells with cis-dichlorodiammineplatinum (II) and mitomycin C. Cancer Res 1980; 40: 1165-1168.
72. Braun J, Hahn GM: Enhanced cell killing by bleomycin and 43 degrees hyperthermia and the inhibition of recovery from potentially lethal damage. Cancer Res 1975; 35: 2921-2927.
73. Umemura S, Kawabata K, Sasaki K, et al: Recent advances in sonodynamic approach to cancer therapy. Ultrason Sonochem 1996; 3: S 187-S 1991.
74. Shen RN, Lu L, Wu B, et al: Effects of interleukin 2 treatment combined with local hyperthermia in mice inoculated with Lewis lung carcinoma cells. Cancer Res 1990; 50: 5027-5030.
75. Cheng SQ, Zhou XD, Tang ZY, et al: Iodized oil enhances the thermal effect of high-intensity focused ultrasound on ablating experimental liver cancer. J Cancer Res Clin Oncol 1997; 123: 639-644.
76. Feril Jr. L, Kondo T, Zhao QL, et al: Enhancement of hyperthermia-induced apoptosis by nonthermal effects of ultrasound. Cancer Lett 2002; 178: 63-70.
77. Kim SH, Kim JH, Hahn EW: Selective potentiation of hyperthermic killing of hypoxic cells by 5-thio-D-glucose. Cancer Res 1978; 38: 2935-2938.
78. Knapp W, Debatin J, Helus F, et al: Increased thermal response to ultrasound in the Walker carcinosarcoma treated with vasoactive'drugs. Cancer Res 1989; 49: 1768-1772.
79. Berthold F, Berthold R, Matter I, et al: Effect of spleen exposure to ultrasound on cellular and antibodymediated immune reactions in man. Immunol 1982; 162: 46-55.
80. Sietses C, Eijsbouts QAJ, von Blomberg BM, et al: Ultrasonic energy vs. monopolar electrosurgery in laparoscopic cholecystectomy: influence on the postoperative systemic immune response. Surg Endosc 2001; 15: 69-71.
81. Stewart HF, Moore Jr RM: Development of health risk evaluation data for diagnostic ultrasound: a historical perspective. J Clin Ultrasound 1984; 12: 493-500.
82. Child SZ, Hare JD, Carstensen EL, et al: Test for the effects of diagnostic ultrasound on the immune response of mice. Clin Immunol Immunopathol 1981; 18: 299-302.
83. Miller MW, Miller DL, Brayman AA: A review of in vitro bioeffects of inertial ultrasonic cavitation from a mechanistic perspective. Ultrasound Med Biol 1996; 22: 1131-1154.
84. Worle K, Steinbach P, Hofstadter F: The combined effects of high-energy shock waves and cytostatic drugs or cytokines on human bladder cancer cells. Br J Cancer 1994; 69: 58-65.
85. Rahman M: In vitro effects of high energy shock wave alone and combined with anticancer drugs on human bladder cancer cells. Urol Int 1994; 53: 12-17.
86. Wilmer A, Gambihler S, Delius M, Brendel W: In vitro cytotoxic activity of lithotripter shock waves combined with adriamycin or with cisplatin on L 1210 mouse leukemia cells. J Cancer Res Clin Oncol 1989; 115: 229-234.
87. Oosterhof GO, Smits GA, de Ruyter JE, et al: The in vitro effect of electromagnetically generated shock waves (Lithostar) on the Dunning R 3327 PAT-2 rat prostatic cancer cell-line: a potentiating effect on the in vitro cytotoxicity of vinblastin. Urol Res 1989; 17: 13-19.
88. Prat F, Sibille A, Luccioni C, et al: Increased chemocytotoxicity to colon cancer by shock waveinduced cavitation. Gastroenterology 1994; 106: 937-944.
89. Oosterhof GO, Smits GA, de Ruyter AE, et al: In vivo effects of high energy shock waves on urological tumors: an evaluation of treatment modalities. J Urol 1990; 144: 785-789.
90. Weiss N, Delius M, Gambihler S, et al: Effect of shock waves and cisplatin on cisplatin-sensitive and-resistant rodent tumors in vivo. Int J Cancer 1994; 58: 693-699.
91. Maruyama M, Asano T, Uematsu T, et al: The effect of high-energy shock wave therapy combined with cisplatin on mouse hepatoma. Jpn J Surg 1995; 25: 987-988.
92. Hoshi S, Orikasa S, Kuwahara M, et al: Shock wave and THP-adriamycin for treatment of rabbit's bladder cancer. Jpn J Cancer Res 1992; 83: 248-250.
93. Kato M, Ioritani N, Suzuki T, et al: Mechanism of anti-tumor effect of combination of bleomycin and shock waves. Jpn J Cancer Res 2000; 91: 1065-1072.
94. Oosterhof GO, Smits GA, de Ruyter AE, et al: Effects of high-energy shock waves combined with biological response modifiers in different human kidney cancer xenografts. Ultrasound Med Biol 1991; 17: 391-399.
95. Hoshi S, Orikasa S, Suzuki K, et al: High-energy underwater shock wave treatment for internal iliac muscle metastasis of prostatic cancer: a first clinical trial. Jpn J Cancer Res 1995; 86: 424-428.
96. Kambe M, Ioritani N, Shirai S, et al: Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC). In Vivo 1996; 10: 369-375.
97. Randazzo RF, Chaussy CG, Fuchs GJ, et al: The in vitro and in vivo effects of extracorporeal shock waves on malignant cells. Urol Res 1988; 16: 419-426.
98. Kambe M, Ioritani N, Kanamaru R: Enhancement of chemotherapeutic effects with focused shock waves: extracorporeal shock wave chemotherapy (ESWC). Hum Cell 1997; 10: 87-93.
99. Delius M, Adams G: Shock wave permeabilization with ribosome inactivating proteins: a new approach to tumor therapy. Cancer Res 1999; 59: 5227-5232.
100. Suzuki K, Orikasa S, Hoshi S, et al: Shock wave therapy of the rabbit VX 2 bladder cancer-THP-ADM concentration in the tissue after combination therapy of THP-AD M and shock wave [in Japanese]. Nippon Hinyokika Gakkai Zasshi 1993; 84: 1007-1012. Abstract in English.
101. Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H: Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990; 47: 219-231.
102. Fosmire H, Hynynen K, Drach GW, et al: Feasibility and toxicity of transrectal ultrasound hyperthermia in the treatment of locally advanced adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993; 26: 253-259.
103. Gelet A, Chapelon JY, Bouvier R, et al: Treatment of prostate cancer with transrectal focused ultrasound: early clinical experience. Eur Urol 1996; 29: 174-183.
104. Gelet A, Chapelon JY, Bouvier R, et al: Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: preliminary results. J Urol 1999; 161: 156-162.
105. Beerlage HP, van Leenders GJ, Oosterhof GO, et al: High-intensity focused ultrasound (HIFU) followed after one to two weeks by radical retropubic prostatectomy: results of a prospective study. Prostate 1999; 39: 41-46.
106. Gelet A, Chapelon JY, Bouvier R, et al: Transrectal high-intensity focused ultrasound: minimally invasive therapy of localized prostate cancer. J Endourol 2000; 14: 519-528.
107. Hurwitz MD, Kaplan ID, Svensson GK, et al: Feasibility and patient tolerance of a novel transrectal ultrasound hyperthermia system for treatment of prostate cancer. Int J Hyperthermia 2001; 17: 31 -37.
108. Uchida T, Sanghvi NT, Gardner TA, et al: Transrectal high-intensity focused ultrasound for treatment of patients with stage Tlb-2n0m0 localized prostate cancer: a preliminary report. Urology 2002; 59: 394-398.
109. Beerlage HP, Thuroff S, Debruyne FM, et al: Transrectal high-intensity ultrasound using the Ablatherm device in the treatment of localized prostate carcinoma. Urology 1999; 54: 273-277.
110. Madersbacher S, Kratzik C, Susani M, et al: Transcutaneous high-intensity focused ultrasound and irradiation: an organ-preserving treatment of cancer in a solitary testis. Eur Urol 1998; 33: 195-201.
111. Vallancien G, Harouni M, Guillonneau B, et al: Ablation of superficial bladder tumors with focused extracorporial pyrotherapy. Urology 1996; 47: 204-207.
112. Myerson RJ, Straube WL, Moros EG, et al: Simultaneous superficial hyperthermia and external radiotherapy: report of thermal dosimetry and tolerance to treatment. Int J Hyperthermia 1999; 15: 251-266.
113. Guthkelch AN, Carter LP, Cassady JR, et al: Treatment of malignant brain tumors with focused ultrasound hyperthermia and radiation: results of a phase I trial. J Neurooncol 1991; 10: 271-284.
114. van Dam PA, Tjalma W, Weyler J, et al: Ultraradical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: a prospective randomized trial. Am J Obstet Gynecol 1996; 174: 943-950.
115. Rosberger DF, Coleman DJ, Silverman R, et al: Immunomodulation in choroidal melanoma: reversal of inverted CD 4/CD 8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther 1994; 5: 59-68.
116. Visioli AG, Rivens IH, ter Haar GR, et al: Preliminary results of a phase I dose escalation clinical trial using focused ultrasound in the treatment of localized tumours. Eur J Ultrasound 1999; 9: 11-18.
117. Pilepich MV, Jones KG, Emami BN, et al: Interaction of bleomycin and hyperthermia-results of a clinical pilot study. Int J Radiat Oncol Biol Phys 1989; 16: 211-213.